ArticleTropical animal health and production2026
Bovine appeasing pheromone mitigates long-distance transport stress to improve health and growth performance in beef cattle.
Article in Tropical animal health and production, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transportation inevitable in modern beef industry disrupts physiological homeostasis and compromises cattle health. This study evaluated bovine appeasing pheromone (BAP) in alleviating transport-induced dysfunctions. Herein, 120 Simmental crossbred bulls (235 ± 5 kg) underwent a 1402-km transport trial with or without BAP treatment (5 mL topically). Data showed BAP decreased (p < 0.01) serum cortisol and haptoglobin levels on day 1 (D1) and D14 post-transport, with cortisol reduced by 32.99% and 47.09%, and haptoglobin by 51.67% and 53.48%, respectively. Concurrently, BAP lowered (p < 0.05) serum IL-1 (by 57.01%) and TNF-α (by 44.12%) on D1, reduced IL-1 (by 22.24%), IL-6 (by 15.18%), and TNF-α (by 23.29%) on D14, and increased (p < 0.01) IgG by 38.58% on D14. Consequently, BAP facilitated metabolic recovery, elevating (p < 0.01) serum glucose and insulin-like growth factor-1 from D14 to D35. Clinically, BAP reduced (p < 0.01) the incidence and duration of respiratory symptoms, increasing (p < 0.05) total feed intake. In summary, BAP protects beef cattle against transport stress-induced health impairment and growth decline by maintaining physiological homeostasis, offering a highly practical intervention to optimize animal welfare in the modern beef industry.
Indexed as
Identifiers
42773304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.